Banner-cancer

National media interest in new rainforest cancer compound

Results from promising human trials offer hope for tumour treatment

CREATED NEW NATIONAL INTEREST IN LOCAL TREATMENT FOR SOLID TUMOURS IN HUMANS.

SHARE THIS CASE STUDY

The Palin Communications team has been helping long term client, Australian life sciences company QBiotics, report good progress in developing EBC-46 as a potential local treatment for solid tumours in humans.

QBiotics is a public, unlisted company based in Brisbane, Queensland. EBC-46 is a novel compound with anticancer properties that is derived from a plant unique to Australia’s tropical rainforest.

Now, a multi-centre human trial is showing encouraging results and Palin supported QBiotics to implement a proactive media relations program leveraging the results. The PR coincided with (and supported) another round of successful capital raising for the company in late August.

Results

  • National TV news exclusive with Channel 7 secured
  • Ch7 News Facebook post promoting the story which was viewed over 1 million times
  • Widespread consumer and healthcare professional media coverage including stories in The Australian, The West Australian, Yahoo 7, The Cairns Post, Biotech Daily, Pharma Dispatch and other key business publications
  • Over $16 million raised during the latest capital raising activity.
CLICK TO FIND OUT HOW WE CAN HELP YOU

Save Time. Stay updated.